AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 321177 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg)
Number of subjects: 230
Study 321177 — intervention group
Group type: COMPARATOR
Intervention: Codeine (60 mg)
Number of subjects: 230
Study 321177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 31736077 — intervention group
Group type: EXPERIMENTAL
Intervention: Morus nigra L. (MN) leaf powder 250 mg for 60 days
Number of subjects: 62
Study 31736077 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) 1 mg estradiol for 60 days
Number of subjects: 62
Study 31736077 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 60 days
Number of subjects: 62
Study 29897622 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent education program consisting of six 2.5-hour sessions
Number of subjects: 56
Study 29897622 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 56
Study 28680091 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized granular powder (GP) of Salvia miltiorrhiza (SM)
Number of subjects: 0
Study 28680091 — intervention group
Group type: COMPARATOR
Intervention: Traditional decoction (TD) of Salvia miltiorrhiza (SM)
Number of subjects: 0
Study 25586298 — intervention group
Group type: EXPERIMENTAL
Intervention: ropinirole prolonged release (PR) administered for 24 weeks as adjunctive to levodopa
Number of subjects: 295
Study 23884830 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-virgin olive oil enriched with antioxidants
Number of subjects: 8
Study 23884830 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-virgin olive oil enriched with probiotics
Number of subjects: 8
Study 21740570 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine phosphate-trimethoprim (DPT)
Number of subjects: 418
Study 21740570 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 418
Study 19824601 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-incision technique
Number of subjects: 40
Study 16708725 — intervention group
Group type: COMPARATOR
Intervention: Metal matrix and wooden wedge
Number of subjects: 23
Study 16708725 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyester matrix and reflective wedge
Number of subjects: 23
Study 15636080 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of WHO/UNICEF Breastfeeding Hospital Initiative (BFHI)
Number of subjects: 0
Study 15636080 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding support groups activity (1999-2000)
Number of subjects: 0
Study 11419238 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% sevoflurane
Number of subjects: 20
Study 9847819 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis prevention program
Number of subjects: 31
Study 9847819 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study 7980764 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior myocardial infarction
Number of subjects: 2466
Study 7980764 — intervention group
Group type: COMPARATOR
Intervention: Nonanterior myocardial infarction
Number of subjects: 2466
Study 2599475 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan with Corynebacterium parvum
Number of subjects: 186
Study 2599475 — intervention group
Group type: COMPARATOR
Intervention: melphalan without Corynebacterium parvum
Number of subjects: 186
Study 30589922 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone implant after switching from aflibercept
Number of subjects: 49
Study 30589922 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept after switching from bevacizumab
Number of subjects: 49
Study 28270173 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG + Probiotic Mixture (PM)
Number of subjects: 55
Study 28270173 — intervention group
Group type: COMPARATOR
Intervention: PEG only
Number of subjects: 55
Study 28270173 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG + PM
Number of subjects: 55
Study 25695576 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative smoking cessation intervention (brief counseling, brochures, referral to quitline, 6-week transdermal nicotine replacement)
Number of subjects: 168
Study 25695576 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 168
Study 23263458 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g/kg alcohol
Number of subjects: 0
Study 23263458 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg alcohol
Number of subjects: 0
Study 23263458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21525768 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics (1 g of Bifidobacterium breve strain Yakult three times a day and 5.5 g of GOS once a day for one year)
Number of subjects: 41
Study 21525768 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 41
Study 21525768 — intervention group
Group type: COMPARATOR
Intervention: Control (no synbiotics)
Number of subjects: 41
Study 17892374 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5 mg intravenously once yearly
Number of subjects: 7736
Study 17892374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7736
Study 16490030 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive diabetes mellitus treatment and good glycemic control
Number of subjects: 25
Study 12859608 — intervention group
Group type: EXPERIMENTAL
Intervention: Open kinetic chain tonification exercises (group I)
Number of subjects: 60
Study 12859608 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed kinetic chain tonification exercises (group II)
Number of subjects: 60
Study 11228790 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiolytic premedication (midazolam 7.5 mg, midazolam 15 mg, diazepam 15 mg)
Number of subjects: 1263
Study 11228790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1263
Study 9931829 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalograde tibial nail
Number of subjects: 0
Study 9931829 — intervention group
Group type: COMPARATOR
Intervention: Plate osteosynthesis
Number of subjects: 0
Study 8044953 — intervention group
Group type: COMPARATOR
Intervention: Intensive vascular training alone
Number of subjects: 44
Study 8044953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pentoxifylline (200 mg over 2 hours BID) with intensive vascular training
Number of subjects: 44
Study 8044953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (40 micrograms over 2 hours BID) with intensive vascular training
Number of subjects: 44
Study 8044953 — intervention group
Group type: COMPARATOR
Intervention: Follow-up for all groups after 1 year
Number of subjects: 44
Study 2647319 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex scanning
Number of subjects: 47
Study 30755171 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified full enteral nutrition (standard full EN in conjunction with prokinetic drug)
Number of subjects: 600
Study 30755171 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive underfeeding (40 to 60% of estimated caloric requirements)
Number of subjects: 600
Study 30755171 — intervention group
Group type: COMPARATOR
Intervention: Standard full enteral nutrition (advancement to target nutrition goals)
Number of subjects: 600
Study 30755171 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (modified full EN, permissive underfeeding, standard full EN)
Number of subjects: 600
Study 28364415 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating white noise at 12 Hz (targeting slow spindles)
Number of subjects: 0
Study 28364415 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating white noise at 15 Hz (targeting fast spindles)
Number of subjects: 0
Study 28364415 — intervention group
Group type: COMPARATOR
Intervention: Constant white noise (50 Hz control condition)
Number of subjects: 0
Study 26482384 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Exercise (HIE)
Number of subjects: 47
Study 26482384 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Exercise (MIE)
Number of subjects: 47
Study 25163498 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of roasted flaxseed powder for 3 months
Number of subjects: 50
Study 25163498 — intervention group
Group type: COMPARATOR
Intervention: Control group (similar dietary guidelines)
Number of subjects: 50
Study 23095069 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional oral health care (POHC) treatment by dental hygienists (n = 21)
Number of subjects: 40
Study 23095069 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 19)
Number of subjects: 40
Study 19380445 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI(10) and PCI(20) - combination of CP-751,871 (10 to 20 mg/kg), paclitaxel (200 mg/m²), and carboplatin (AUC 6) every 3 weeks for up to six cycles.
Number of subjects: 156
Study 19380445 — intervention group
Group type: COMPARATOR
Intervention: PC - paclitaxel and carboplatin alone.
Number of subjects: 156
Study 19380445 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI(20) - nonrandomized single-arm cohort of 30 patients with nonadenocarcinoma tumor histology.
Number of subjects: 156
Study 19380445 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with squamous cell carcinoma histology.
Number of subjects: 156
Study 19380445 — intervention group
Group type: COMPARATOR
Intervention: CP-751,871 after disease progression in PC group.
Number of subjects: 156
Study 19380445 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI(20)/PC hazard ratio for progression-free survival.
Number of subjects: 156
Study 17447178 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline exposed physicians
Number of subjects: 1319
Study 17447178 — intervention group
Group type: COMPARATOR
Intervention: Control group (guideline naive physicians)
Number of subjects: 1319
Study 15173031 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin prophylaxis
Number of subjects: 100
Study 15173031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11965280 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation with measles vaccine
Number of subjects: 0
Study 10453786 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-arm index (AAI) less than 1.0
Number of subjects: 62
Study 10453786 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-arm index (AAI) greater than 1.0
Number of subjects: 62
Study 10453786 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-arm index (AAI)
Number of subjects: 62
Study 7874633 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncemented total hip replacement
Number of subjects: 0
Study 7874633 — intervention group
Group type: COMPARATOR
Intervention: Cemented total hip replacement
Number of subjects: 0
Study 2219758 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 266
Study 2219758 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin with dipyridamol
Number of subjects: 266
Study 2219758 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose (Control)
Number of subjects: 266
Study 341337 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 950
Study 341337 — intervention group
Group type: COMPARATOR
Intervention: Piperazine citrate
Number of subjects: 950
Study 341337 — intervention group
Group type: COMPARATOR
Intervention: Pyrantel pamoate
Number of subjects: 950
Study 341337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 950
Study 31784354 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg amisulpride (MDDAmisulpride)
Number of subjects: 31
Study 31784354 — intervention group
Group type: COMPARATOR
Intervention: Placebo (MDDPlacebo)
Number of subjects: 31
Study 31784354 — intervention group
Group type: COMPARATOR
Intervention: Placebo (HCPlacebo)
Number of subjects: 31
Study 30919377 — intervention group
Group type: EXPERIMENTAL
Intervention: taTME
Number of subjects: 107
Study 30919377 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic TME
Number of subjects: 107
Study 30919377 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 107
Study 28423174 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (2 mg/kg/d) for 16 weeks
Number of subjects: 34
Study 28423174 — intervention group
Group type: COMPARATOR
Intervention: Steroid (2 mg/kg/d) for 16 weeks
Number of subjects: 34
Study 25668220 — intervention group
Group type: EXPERIMENTAL
Intervention: PLUNGE intervention (n = 97 students)
Number of subjects: 168
Study 25668220 — intervention group
Group type: COMPARATOR
Intervention: 7-week wait-list control (n = 71 students)
Number of subjects: 168
Study 23390999 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep hypothermic circulatory arrest (DHCA)
Number of subjects: 12
Study 23390999 — intervention group
Group type: COMPARATOR
Intervention: Continuous antegrade cerebral perfusion (ACP)
Number of subjects: 12
Study 21549518 — intervention group
Group type: EXPERIMENTAL
Intervention: 50.4 Gy
Number of subjects: 203
Study 21549518 — intervention group
Group type: EXPERIMENTAL
Intervention: 64.8 Gy
Number of subjects: 203
Study 21549518 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-deletion of 1p19q
Number of subjects: 203
Study 19766812 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Mosaic (MM) porcine valve
Number of subjects: 152
Study 19766812 — intervention group
Group type: COMPARATOR
Intervention: Edwards Perimount (EP) bovine valve
Number of subjects: 152
Study 17701638 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated teaching session on clinical decision analysis
Number of subjects: 132
Study 17701638 — intervention group
Group type: COMPARATOR
Intervention: Surgical rotations (control)
Number of subjects: 132
Study 15579519 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin treatment
Number of subjects: 2696
Study 15579519 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hemoglobin targets (> 130 g/L)
Number of subjects: 2696
Study 15579519 — intervention group
Group type: COMPARATOR
Intervention: Lower hemoglobin targets (< 120 g/L)
Number of subjects: 2696
Study 11179530 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril treatment
Number of subjects: 0
Study 11179530 — intervention group
Group type: COMPARATOR
Intervention: Control (no quinapril treatment)
Number of subjects: 0
Study 9672506 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based nutrition education program
Number of subjects: 261
Study 9672506 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard nutrition counseling
Number of subjects: 261
Study 9672506 — intervention group
Group type: COMPARATOR
Intervention: At-risk control group
Number of subjects: 261
Study 9751014 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus IFN‐alpha 3 micrograms (n = 232 patients)
Number of subjects: 704
Study 9751014 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha 2b 3 million units (n = 240 patients)
Number of subjects: 704
Study 9751014 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-treatment HCV RNA response
Number of subjects: 704
Study 1884902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) treatment for a mean of 13.8 months
Number of subjects: 0
Study 1884902 — intervention group
Group type: COMPARATOR
Intervention: Former CsA patients
Number of subjects: 0
Study 1884902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) treatment
Number of subjects: 0
Study 6356856 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimazosin
Number of subjects: 96
Study 6356856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 6356856 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 96
Study 30958508 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg per day)
Number of subjects: 7112
Study 30958508 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 7112
Study 28125095 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin concentration in colostrum
Number of subjects: 346
Study 28125095 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin concentration in transitional milk
Number of subjects: 346
Study 28125095 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin concentration at 1 month postpartum
Number of subjects: 346
Study 28125095 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin concentration at 2 months postpartum
Number of subjects: 346
Study 28125095 — intervention group
Group type: COMPARATOR
Intervention: Comparison of LF concentration across stages of lactation
Number of subjects: 346
Study 28125095 — intervention group
Group type: COMPARATOR
Intervention: Association of maternal factors with LF concentration
Number of subjects: 346
Study 26795413 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher oxygen saturation targeting (91‐95%)
Number of subjects: 38
Study 26795413 — intervention group
Group type: COMPARATOR
Intervention: Lower oxygen saturation targeting (85‐89%)
Number of subjects: 38
Study 24710621 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 124
Study 22883004 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of valproic acid (VPA) and lamotrigine (LTG)
Number of subjects: 134
Study 20417262 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 0
Study 20417262 — intervention group
Group type: COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine (PCV7)
Number of subjects: 0
Study 20417262 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13) and 7-valent pneumococcal conjugate vaccine (PCV7)
Number of subjects: 0
Study 18486222 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity laser treatment
Number of subjects: 225
Study 18486222 — intervention group
Group type: COMPARATOR
Intervention: Observation (control)
Number of subjects: 225
Study 15695125 — intervention group
Group type: COMPARATOR
Intervention: Stenting
Number of subjects: 1203
Study 15695125 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1203
Study 15695125 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1203
Study 14694970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical PGE2 (dinoprostone 0.5 mg) by gel (n = 66)
Number of subjects: 115
Study 14694970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal PGE2 (dinoprostone 10 mg) by pessary (n = 49)
Number of subjects: 115